| [1] |
王长爽, 党利, 刘付琼. 急性白血病患儿的凝血功能、免疫功能及发病相关因素分析[J]. 癌症进展, 2022, 20(7):709-711.
|
| [2] |
高姗, 林江, 李芳芳, 等. 急性白血病儿童化学治疗期间脓毒症病原学特点及危险因素[J]. 中国感染控制杂志, 2023, 22(8):945-952.
|
| [3] |
Zhang N, Wen D, Wang T, et al. Disparities in incidence and mortality of pediatric acute lymphoblastic leukemia across countries with different incomes[J]. Leukemia, 2024, 38(12):2731-2734.
|
| [4] |
中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会白血病淋巴瘤学组, 王建祥, 等. 中国成人急性淋巴细胞白血病诊断与治疗指南(2024年版)[J]. 中华血液学杂志, 2024, 45(5):417-429.
|
| [5] |
中华医学会血液学分会白血病淋巴瘤学组, 金洁, 马军, 等. 中国复发难治性急性髓系白血病诊疗指南(2023年版)[J]. 中华血液学杂志, 2023, 44(9):713-716.
|
| [6] |
方婧, 肖镇冬, 徐修云, 等. 妊娠期急性白血病9例临床分析[J]. 中华妇产科杂志, 2024, 59(9):719-722.
|
| [7] |
杨文钰, 竺晓凡. 中国儿童急性白血病的诊治现状及展望[J]. 中华医学杂志, 2024, 104(27):2477-2482.
|
| [8] |
胡婉迪, 苏淑芳, 李白, 等. 以面神经麻痹为首发症状的急性白血病患儿的临床分析[J]. 国际输血及血液学杂志, 2024, 47(1):46-53.
|
| [9] |
Mehralizadeh H, Aliparasti M R, Talebi M, et al. WT-1,BAALC,and ERG expressions in Iranian patients with acute myeloid leukemia pre- and post-chemotherapy[J]. Adv Pharm Bull, 2021, 11(1):197-203.
|
| [10] |
Zhang Q, Liu L, Yan H, et al. Prognostic value of the WT-1 gene combined with recurrent cytogenetic genes in acute myeloid leukemia[J]. Immunogenetics, 2023, 75(4):395-401.
|
| [11] |
叶演, 张泽珑, 朱宝行, 等. WT1多肽乳佐剂疫苗的免疫增强效应及其对急性髓系白血病抗肿瘤效应研究[J]. 陆军军医大学学报, 2024, 46(9):1024-1033.
|
| [12] |
方鹏, 高银, 信红亚, 等. WT1基因指导的抢先治疗预防急性髓系白血病移植后复发的疗效及其最佳干预节点[J]. 中南大学学报(医学版), 2024, 49(7):1120-1129.
|
| [13] |
Arber D A, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia[J]. Blood, 2016, 127(20):2391-2405.
|
| [14] |
Zhang S, Tong C, Cao N, et al. Hippocampal transcriptome analysis in a mouse model of chronic unpredictable stress insomnia[J]. Biomedicines, 2025, 13(5):1205.
|
| [15] |
王迎. 《中国成人急性淋巴细胞白血病诊断与治疗指南(2024年版)》解读[J]. 临床血液学杂志, 2024, 37(7):453-456.
|
| [16] |
中华医学会血液学分会白血病淋巴瘤学组, 王建祥, 魏辉. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2023年版)[J]. 中华血液学杂志, 2023, 44(9):705-712.
|
| [17] |
Arai S, Tachibana T, Izumi A, et al. WT1-guided pre-emptive therapy after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia[J]. Int J Hematol, 2024, 120(3):337-346.
|
| [18] |
Ahmed S, Elsherif M, Yassin D, et al. Integration of measurable residual disease by WT1 gene expression and flow cytometry identifies pediatric patients with high risk of relapse in acute myeloid leukemia[J]. Front Oncol, 2024, 14:1340909.
|
| [19] |
Aribi A, Salhotra A, Afkhami M, et al. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens[J]. Leuk Lymphoma, 2023, 64(11):1811-1821.
|
| [20] |
Luo X H, Poiret T, Liu Z, et al. Corrigendum:different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation:impact of CMV infection and leukemia relapse[J]. Front Immunol, 2023, 14:1195142.
|
| [21] |
Ma S, Tang L, Tang H, et al. WT1 and DNMT3A mutations in prognostic significance of acute myeloid leukemia:a meta-analysis[J]. Cancer Biother Radiopharm, 2025, 40(1):22-30.
|